Tag: Biotechnology

VILYA
Global, United States

Vilya Appoints Cyrus Harmon, Ph.D., as Chief Executive Officer

October 17, 2023 08:00 AM Eastern Daylight Time SEATTLE–(BUSINESS WIRE)–VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines thatprecisely target disease biology, today announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer. “I am very excited to join the phenomenal team at Vilya developing new macrocycle drugs” “I am very excited to join the phenomenal team at Vilya developing … Continue reading Vilya Appoints Cyrus Harmon, Ph.D., as Chief Executive Officer

Impact Newswire
ALTO NEUROSCIENCE
Global

Alto Neuroscience Appoints Andrew Dreyfus to Its Board of Directors

– Andrew Dreyfus served as President & Chief Executive Officer for Blue Cross Blue Shield of Massachusetts (BCBSMA), one of the largest independent Blue Cross Blue Shield plans in the U.S. – October 18, 2023 08:00 AM Eastern Daylight Time LOS ALTOS, Calif.–(BUSINESS WIRE)–Alto Neuroscience today announced the appointment of Andrew Dreyfus, former president and CEO of BCBSMA, to the company’s board of directors as an … Continue reading Alto Neuroscience Appoints Andrew Dreyfus to Its Board of Directors

Impact Newswire
Agomab
Europe, Global

Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

— Round led by Fidelity Management & Research Company with participation from new investors EQT Life Sciences, Canaan and Dawn Biopharma, a platform controlled by KKR, as well as existing investors – — Proceeds will support clinical Phase 2 stage lead candidate AGMB-129 for Fibrostenosing Crohn’s Disease and the development of a highly innovative pipeline of anti-fibrotic and regenerative therapies, including AGMB-447 for idiopathic pulmonary … Continue reading Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

Impact Newswire
Nirrin
United States

Nirrin appoints Greg Crescenzi as Chief Executive Officer

Company strengthens life science leadership to drive high-precision tunable laser spectroscopy (HPTLS) platform commercialization October 10, 2023 09:00 AM Eastern Daylight Time BILLERICA, Mass. – Nirrin Technologies, a company developing analytical systems to transform analysis for bioprocessing operations, announced that Greg Crescenzi has joined the company as its Chief Executive Officer. “Greg brings 30 years of strategic leadership in life science and biomanufacturing, and a long-standing history … Continue reading Nirrin appoints Greg Crescenzi as Chief Executive Officer

Impact Newswire
Sibylla Biotech
United States

Sibylla Biotech Appoints Sonia Poli as Chief Scientific Officer

October 10, 2023 05:00 AM Eastern Daylight Time MILAN – Sibylla Biotech today announces the appointment of Sonia Poli, Ph.D., as Chief Scientific Officer (CSO). Dr. Poli brings more than two decades of international experience in pharmaceutical research and development, with broad knowledge spanning small molecule drug design, translational science, and early- to late-stage clinical development. As a seasoned pharmaceutical R&D executive, Dr. Poli has held … Continue reading Sibylla Biotech Appoints Sonia Poli as Chief Scientific Officer

Impact Newswire
LIMMATECH BIOLOGICS AG
Europe

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

October 09, 2023 04:00 AM Eastern Daylight Time SCHLIEREN, Switzerland – LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against … Continue reading LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

Impact Newswire
Odyssey Therapeutics
United States

Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer

October 04, 2023 08:00 AM Eastern Daylight Time BOSTON – Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer. In this role, Dr. Sokolove will develop, lead and drive the development strategy and execution of all Odyssey’s clinical assets. Additionally, he will be responsible for selecting, prioritizing and accelerating … Continue reading Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer

Impact Newswire
Nuvig Therapeutics
United States

Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer

Physician and biopharmaceutical leadership executive with extensive experience in novel drug development, operations management, and team building October 04, 2023 09:00 AM Eastern Daylight Time REDWOOD CITY, Calif. – Nuvig Therapeutics, Inc., a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer. Dr. Glicklich has more than 25 years of … Continue reading Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer

Impact Newswire